[
  {
    "ts": null,
    "headline": "Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?",
    "summary": "Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...",
    "url": "https://finnhub.io/api/news?id=4f2335b8fe5592882d161016dbec6a6c12fbd03e50978f5b6f6541bafb9531a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732795228,
      "headline": "Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?",
      "id": 131686288,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/7137ef364be97d9882cfa4ec57169a99",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...",
      "url": "https://finnhub.io/api/news?id=4f2335b8fe5592882d161016dbec6a6c12fbd03e50978f5b6f6541bafb9531a9"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Fund Q3 2024 Commentary",
    "summary": "Janus Henderson Global Life Sciences Fund returned 5.39% and the MSCI World Health Care IndexSM returned 5.70%. Read more here.",
    "url": "https://finnhub.io/api/news?id=6f33758f49e72ec36ead70f5b29bda23bdb6b5a987e6dc45a309c6604763ed75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732784100,
      "headline": "Janus Henderson Global Life Sciences Fund Q3 2024 Commentary",
      "id": 131684758,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488432016/image_1488432016.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Janus Henderson Global Life Sciences Fund returned 5.39% and the MSCI World Health Care IndexSM returned 5.70%. Read more here.",
      "url": "https://finnhub.io/api/news?id=6f33758f49e72ec36ead70f5b29bda23bdb6b5a987e6dc45a309c6604763ed75"
    }
  },
  {
    "ts": null,
    "headline": "Alumis: A Best-In-Class TYK2 Inhibitor",
    "summary": "Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet requires caution on safety data.",
    "url": "https://finnhub.io/api/news?id=dd78cd34088fd16be6313c0288e0525f2c773e848d7452ec774ae59311950ef7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732774005,
      "headline": "Alumis: A Best-In-Class TYK2 Inhibitor",
      "id": 131682243,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1388000572/image_1388000572.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet requires caution on safety data.",
      "url": "https://finnhub.io/api/news?id=dd78cd34088fd16be6313c0288e0525f2c773e848d7452ec774ae59311950ef7"
    }
  }
]